Nuvalent (NASDAQ:NUVL) Trading Down 9.5% – What’s Next?

Nuvalent, Inc. (NASDAQ:NUVL)’s stock price dropped 9.5% during mid-day trading on Monday . The company traded as low as $99.86 and last traded at $99.9550. Approximately 363,632 shares were traded during trading, a decline of 35% from the average daily volume of 561,873 shares. The stock had previously closed at $110.39.

Analyst Ratings Changes

NUVL has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research note on Tuesday, April 21st. Cantor Fitzgerald boosted their price target on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Wedbush reissued an “outperform” rating and issued a $125.00 price target on shares of Nuvalent in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $155.00 price target on shares of Nuvalent in a report on Tuesday, April 21st. Finally, Wells Fargo & Company initiated coverage on Nuvalent in a report on Monday, March 30th. They issued an “overweight” rating and a $116.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $140.29.

Nuvalent Stock Performance

The company has a fifty day moving average of $103.03 and a two-hundred day moving average of $103.31. The company has a market cap of $7.94 billion, a PE ratio of -16.58 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the firm posted ($1.18) earnings per share. On average, equities analysts forecast that Nuvalent, Inc. will post -5.74 EPS for the current year.

Insider Buying and Selling

In other Nuvalent news, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $101.69, for a total value of $3,050,700.00. Following the transaction, the chief executive officer owned 324,879 shares of the company’s stock, valued at $33,036,945.51. This represents a 8.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the transaction, the insider directly owned 65,604 shares in the company, valued at $6,854,305.92. This trade represents a 4.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 80,023 shares of company stock worth $8,235,217. 5.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nuvalent

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after acquiring an additional 639,264 shares during the last quarter. Wellington Management Group LLP grew its position in Nuvalent by 7.0% in the 4th quarter. Wellington Management Group LLP now owns 2,461,823 shares of the company’s stock valued at $247,635,000 after acquiring an additional 160,958 shares during the last quarter. JPMorgan Chase & Co. grew its position in Nuvalent by 32.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after acquiring an additional 545,542 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Nuvalent by 18.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock valued at $215,962,000 after acquiring an additional 336,518 shares during the last quarter. Finally, RA Capital Management L.P. grew its position in Nuvalent by 50.8% in the 4th quarter. RA Capital Management L.P. now owns 1,880,057 shares of the company’s stock valued at $189,115,000 after acquiring an additional 633,601 shares during the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.